Skip to main content

Table 5 Slope and intercept from the exposure-response analysis of placebo-corrected QTcN change from baseline by dose

From: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

 

Slope [ms/(nmol/L)]

 

Predicted value of placebo-corrected change from baseline QTcN (ms) at gMean of Cmax

Treatment

Intercept (ms)

Estimate

95% CI

gMean of Cmax(nmol/L)

Estimate

90% CI

Empagliflozin 25 mg

0.35

-0.0007

-0.0043, 0.0029

768

-0.20

-1.65, 1.24

Empagliflozin 200 mg

-0.60

-0.0000

-0.0005, 0.0005

4860

-0.64

-2.33, 1.05

  1. Predicted values and confidence intervals (CI) determined by the exposure-response relationship of empagliflozin (25 mg or 200 mg treatment group). Data from the full analysis set. QTcN, population heart rate-corrected QT interval.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840